Objective: We investigated the effect of a potent TGFβ (transforming growth factor β) inhibitor peptide (P144) from the betaglycan/TGFβ receptor III on aortic aneurysm development in a Marfan syndrome mouse model. Approach and Results: We used a chimeric gene encoding the P144 peptide linked to apolipoprotein A-I via a flexible linker expressed by a hepatotropic adeno-associated vector. Two experimental approaches were performed: (1) a preventive treatment where the vector was injected before the onset of the aortic aneurysm (aged 4 weeks) and followed-up for 4 and 20 weeks and (2) a palliative treatment where the vector was injected once the aneurysm was formed (8 weeks old) and followed-up for 16 weeks. We evaluated the aortic root diameter by echocardiography, the aortic wall architecture and TGFβ signaling downstream effector expression of pSMAD2 and pERK1/2 by immunohistomorphometry, and Tgfβ1 and Tgfβ2 mRNA expression levels by real-time polymerase chain reaction. Marfan syndrome mice subjected to the preventive approach showed no aortic dilation in contrast to untreated Marfan syndrome mice, which at the same end point age already presented the aneurysm. In contrast, the palliative treatment with P144 did not halt aneurysm progression. In all cases, P144 improved elastic fiber morphology and normalized pERK1/2-mediated TGFβ signaling. Unlike the palliative treatment, the preventive treatment reduced Tgfβ1 and Tgfβ2 mRNA levels. Conclusions: P144 prevents the onset of aortic aneurysm but not its progression. Results indicate the importance of reducing the excess of active TGFβ signaling during the early stages of aortic disease progression.
Williams–Beuren syndrome (WBS) is a rare disorder caused by a recurrent microdeletion with hallmarks of cardiovascular manifestations, mainly supra-valvular aortic stenosis (SVAS). Unfortunately, there is currently no efficient treatment. We investigated the effect of chronic oral treatment with curcumin and verapamil on the cardiovascular phenotype of a murine model of WBS harbouring a similar deletion, CD (complete deletion) mice. We analysed systolic blood pressure in vivo and the histopathology of the ascending aorta and the left ventricular myocardium to determine the effects of treatments and their underlying mechanism. Molecular analysis showed significantly upregulated xanthine oxidoreductase (XOR) expression in the aorta and left ventricular myocardium of CD mice. This overexpression is concomitant with increased levels of nitrated proteins as a result of byproduct-mediated oxidative stress damage, indicating that XOR-generated oxidative stress impacts the pathophysiology of cardiovascular manifestations in WBS. Only the combined therapy of curcumin and verapamil resulted in a significant improvement of cardiovascular parameters via activation of the nuclear factor erythroid 2 (NRF2) and reduction of XOR and nitrated protein levels. Our data suggested that the inhibition of XOR and oxidative stress damage could help prevent the severe cardiovascular injuries of this disorder.
Redox stress is involved in the aortic aneurysm pathogenesis in Marfan syndrome (MFS). We recently reported that allopurinol, a xanthine oxidoreductase inhibitor, blocked aortopathy in a MFS mouse model acting as an antioxidant without altering uric acid (UA) plasma levels. Hyperuricaemia is ambiguously associated with cardiovascular injuries as UA, having antioxidant or pro-oxidant properties depending on the concentration and accumulation site. We aimed to evaluate whether hyperuricaemia causes harm or relief in MFS aortopathy pathogenesis. Two-month-old male wild-type (WT) and MFS mice (Fbn1C1041G/+) were injected intraperitoneally for several weeks with potassium oxonate (PO), an inhibitor of uricase (an enzyme that catabolises UA to allantoin). Plasma UA and allantoin levels were measured via several techniques, aortic root diameter and cardiac parameters by ultrasonography, aortic wall structure by histopathology, and pNRF2 and 3-NT levels by immunofluorescence. PO induced a significant increase in UA in blood plasma both in WT and MFS mice, reaching a peak at three and four months of age but decaying at six months. Hyperuricaemic MFS mice showed no change in the characteristic aortic aneurysm progression or aortic wall disarray evidenced by large elastic laminae ruptures. There were no changes in cardiac parameters or the redox stress-induced nuclear translocation of pNRF2 in the aortic tunica media. Altogether, the results suggest that hyperuricaemia interferes neither with aortopathy nor cardiopathy in MFS mice.
Background: Increasing evidence indicates that redox stress participates in MFS aortopathy, though its mechanistic contribution is little known. We reported elevated reactive oxygen species (ROS) formation and NADPH oxidase NOX4 upregulation in MFS patients and mouse aortae. Here we address the contribution of xanthine oxidoreductase (XOR), which catabolizes purines into uric acid and ROS in MFS aortopathy. Methods and Results: In aortic samples from MFS patients, XOR protein expression, revealed by immunohistochemistry, increased in both the tunicae intima and media of the dilated zone. In MFS mice (
Fbn1
C1041G/+ ), aortic XOR mRNA transcripts and enzymatic activity of the oxidase form (XO) were augmented in the aorta of 3-month-old mice but not in older animals. The administration of the XOR inhibitor allopurinol (ALO) halted the progression of aortic root aneurysm in MFS mice. ALO administrated before the onset of the aneurysm prevented its subsequent development. ALO also inhibited MFS-associated endothelial dysfunction as well as elastic fiber fragmentation, fibrotic collagen remodeling, nuclear translocation of pNRF2 and increased 3’-nitrotyrosine levels all occurring in the tunica media. ALO reduced the MFS-associated large aortic production of H 2 O 2 , and NOX4 and MMP2 transcriptional overexpression. Conclusions: Allopurinol interferes in aortic aneurysm progression acting as a potent antioxidant. This study strengthens the concept that redox stress is an important determinant of aortic aneurysm formation and progression in MFS and warrants the evaluation of ALO therapy in MFS patients. HIGHLIGHTS: Xanthine oxidoreductase (XOR) is upregulated in the aortic aneurysm of Marfan syndrome (MFS) both in patients and young mice. Allopurinol halts the formation and progression of aortic aneurysm in MFS mice Allopurinol reduces a variety of oxidative stress-associated molecular reactions. Allopurinol prevents MFS endothelial-dependent vasodilator dysfunction. The antioxidant action of allopurinol suggests its repositioning for pharmacological use in MFS aortopathy. GRAPHICAL
Background: Marfan syndrome (MFS) is a systemic disorder of the connective tissue caused by heterozygous mutations in the FBN1 gene, which encodes fibrillin 1, a glycoprotein that constitutes elastic fibers. MFS does not exhibit sexual dimorphism regarding prevalence; however, it remains unknown whether the paternal or maternal inheritance of the FBN1 mutation affects the cardiovascular pathology of the offspring. In this study, we aimed to determine the impact of the parental origin of the FBN1 mutation on the cardiovascular manifestations of the offspring using the Fbn1C1041G/+ mouse model of MFS. Methods and Results: Four experimental groups were generated by crossing wild-type (WT) and MFS mice to obtain WT and MFS offspring from either a paternal (MFS-P) or maternal (MFS-M) MFS parent. Cardiovascular phenotyping of offspring was performed from childhood to adulthood (from one to six months of age), including echocardiography, tail-cuff plethysmography, histopathology, and canonical (pSmad2) and non-canonical (pERK) TGF-β signaling activity in the aortic tissue. At one month of age, both WT and MFS offspring from MFS-M presented lower body weight than those from MFS-P. However, with age, MFS-M offspring became persistently and significantly overweight. Both MFS-P and MFS-M offspring exhibited a significantly increased aortic root diameter compared with WT offspring; however, this enlargement appeared earlier in MFS-M than in MFS-P offspring. These parental and age-related differences in aortic root diameter were accompanied by increased canonical and non-canonical TGF-β signaling. The cardiac ejection fraction was reduced at early ages in both WT and MFS offspring from MFS-M compared with MFS-P, with the difference persisting only in MFS-M offspring at adulthood. Systolic blood pressure was initially lower in MFS-M offspring across both genotypes. However, it progressively increased, resulting in elevated levels in both WT and MFS offspring from MFS-M by six months of age. Conclusion: Our results indicate the existence of a gestational maternal MFS environmental factor with an early impact on the aorta and heart of MFS offspring. In adulthood, this becomes normalized in the aorta but not in the heart.
Marfan syndrome (MFS) and Williams-Beuren syndrome (WBS) are two genetic diseases of connective tissue caused respectively by mutations in the fibrillin-1 gene (FBN1) and hemizygous loss of the elastin gene (ELN) from an allelic chromosomic deletion. Their respective vascular manifestations are opposed, resulting in thoracic aortic aneurysm in MFS and supravalvular aortic stenosis in WBS. To investigate the interdependence of both essential molecular constituents of elastic fibers, we have generated a double heterozygous mouse model by crossing an MFS female (Fbn1C1041G/+) with a Complete Deletion (CD)-WBS male. We evaluated blood pressure, cardiac and aortic phenotypes, and some physical and cognitive functions in the offspring. Double heterozygous mice (CDMFS) presented the characteristic CD altered behavior. CDMFS mice developed an aneurysm, which progressed over age indistinguishably from MFS mice; CDMFS aortic wall showed a thicker tunica media aorta layer and thinner elastic fibers in accordance with CD mice. The characteristic MFS reduction in vascular smooth muscle cell density is not observed in the CDMFS aorta. CDMFS mice develop the high blood pressure observed in CD animals which does not occur in MFS. Ejection fraction was significantly reduced in MFS, CD, and CDMFS mice compared with WT littermates. Cardiac redox stress markers increased only in CD mice, but not in CDMFS animals. Metalloproteinase-2 protein levels increased only in MFS hearts and partially reduced in CDMFS ones. In conclusion, CDMFS mice exhibited the characteristic phenotypic manifestations of each syndrome, along with the pathological outcomes associated with each elastic fiber component and the respective disease.